NasdaqGS:KPTI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases.


Snowflake Analysis

High growth potential with mediocre balance sheet.

Share Price & News

How has Karyopharm Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KPTI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.6%

KPTI

-1.3%

US Biotechs

0.5%

US Market


1 Year Return

61.8%

KPTI

31.7%

US Biotechs

18.0%

US Market

Return vs Industry: KPTI exceeded the US Biotechs industry which returned 31.7% over the past year.

Return vs Market: KPTI exceeded the US Market which returned 18% over the past year.


Shareholder returns

KPTIIndustryMarket
7 Day-3.6%-1.3%0.5%
30 Day-22.1%-6.0%4.5%
90 Day-23.0%3.8%19.7%
1 Year61.8%61.8%33.8%31.7%20.5%18.0%
3 Year78.7%78.7%34.8%28.3%46.3%36.8%
5 Year11.3%11.3%12.6%4.5%87.2%66.8%

Price Volatility Vs. Market

How volatile is Karyopharm Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Karyopharm Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KPTI ($14.68) is trading below our estimate of fair value ($70.32)

Significantly Below Fair Value: KPTI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: KPTI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: KPTI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KPTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KPTI is overvalued based on its PB Ratio (8.3x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Karyopharm Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

69.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KPTI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: KPTI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: KPTI's is expected to become profitable in the next 3 years.

Revenue vs Market: KPTI's revenue (38.2% per year) is forecast to grow faster than the US market (9.5% per year).

High Growth Revenue: KPTI's revenue (38.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KPTI is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Karyopharm Therapeutics performed over the past 5 years?

-15.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KPTI is currently unprofitable.

Growing Profit Margin: KPTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KPTI is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.

Accelerating Growth: Unable to compare KPTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KPTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.8%).


Return on Equity

High ROE: KPTI has a negative Return on Equity (-145.9%), as it is currently unprofitable.


Next Steps

Financial Health

How is Karyopharm Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: KPTI's short term assets ($317.8M) exceed its short term liabilities ($50.6M).

Long Term Liabilities: KPTI's short term assets ($317.8M) exceed its long term liabilities ($199.6M).


Debt to Equity History and Analysis

Debt Level: KPTI's debt to equity ratio (87.7%) is considered high.

Reducing Debt: Insufficient data to determine if KPTI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KPTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if KPTI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Karyopharm Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KPTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KPTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KPTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KPTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KPTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Michael Kauffman (57 yo)

9.58yrs

Tenure

US$3,231,504

Compensation

Dr. Michael G. Kauffman, M.D., Ph.D. serves as Advisor at Prime Movers Lab and co-founded Karyopharm Therapeutics Inc. in 2008 and has been its Chief Executive Officer since January 05, 2011. Dr. Kauffman ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD3.23M) is about average for companies of similar size in the US market ($USD2.99M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Kauffman
Co-Founder9.58yrsUS$3.23m0.76%
$ 8.1m
Sharon Shacham
Co-Founderno dataUS$3.02m1.03%
$ 11.1m
Christopher Primiano
Executive VP6.42yrsUS$1.62m0.0063%
$ 68.3k
Mansoor Mirza
Clinical Consultant9.83yrsUS$196.77kno data
Michael Mason
Senior VP1.5yrsno datano data
Ran Frenkel
Chief Development Operations Officer5.58yrsUS$6.48m0.048%
$ 514.9k
Cameron Peters
Vice President of Finance1.58yrsno data0.0012%
$ 12.6k
Pierre Sayad
Vice President of Global Medical & Scientific Affairsno datano datano data
Ian Karp
Senior Vice President of Investor & Public Relations2.08yrsno datano data
Tina Beamon
VP & Chief Compliance Officer1.25yrsno datano data
Perry Monaco
Senior Vice President of Salesno datano datano data
Steven Rotman
Chief Human Resources Officerno datano datano data

5.6yrs

Average Tenure

51yo

Average Age

Experienced Management: KPTI's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Kauffman
Co-Founder9.58yrsUS$3.23m0.76%
$ 8.1m
Sharon Shacham
Co-Founderno dataUS$3.02m1.03%
$ 11.1m
Mansoor Mirza
Clinical Consultant9.83yrsUS$196.77kno data
Deepika Pakianathan
Independent Director7.33yrsUS$154.72kno data
Garen Bohlin
Independent Director6.83yrsUS$154.72kno data
Barry Greene
Lead Independent Director5.58yrsUS$189.57k0.0082%
$ 88.5k
Mikael Dolsten
Independent Director5.42yrsUS$142.72kno data
Michael Savona
Member of Scientific Advisory Boardno datano datano data
Richard Paulson
Independent Director0.50yrno datano data
Andrew Kung
Member of Scientific Advisory Board0.25yrno datano data
Cathy Eng
Member of Scientific Advisory Board0.25yrno datano data
Andrew Lassman
Member of Scientific Advisory Board0.25yrno datano data

5.5yrs

Average Tenure

57yo

Average Age

Experienced Board: KPTI's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.


Top Shareholders

Company Information

Karyopharm Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Karyopharm Therapeutics Inc.
  • Ticker: KPTI
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.078b
  • Shares outstanding: 73.48m
  • Website: https://www.karyopharm.com

Number of Employees


Location

  • Karyopharm Therapeutics Inc.
  • 85 Wells Avenue
  • 2nd Floor
  • Newton
  • Massachusetts
  • 2459
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KPTINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2013
25KDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2013

Biography

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment o ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/15 06:22
End of Day Share Price2020/08/14 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.